View Solicitation

Topic: Products to diagnose, prevent or treat novel coronavirus infections
Due Date: Rolling, through 10/31/2020
Budget: Unlimited

While CoronaWatch is not a direct funding mechanism, the U.S. government seeks information from stakeholders on available medical countermeasures in development for COVID-19. A CoronaWatch meeting is held by interactive webinar, in which the presenting team displays slides and engages with government personnel.  A CoronaWatch meeting is encouraged prior to applying for BARDA funding, so that organizations can better align their product development with government priorities.

Request CoronaWatch Meeting

View Solicitation

Description: The NIH Director’s Transformative Research Award Program supports individual scientists or groups of scientists proposing groundbreaking, exceptionally innovative, original, and/or unconventional research with the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies with the potential to produce a major impact on SARS-CoV-2 prevention, preparation, or response. No preliminary data are required.

Topics: Any area of research relevant to the prevention of, preparation for, or response to coronavirus SARS-CoV-2, including behavioral/social science research, research on health disparities, novel therapeutics, and other related topics

Due Dates: 9/30/2020 (opens 8/30/2020)
Budget: Not limited, but must be commensurate with the scope of the proposed research

NIA Multi-site COVID-19 Related Clinical Trial Implementation Grant on Aging-Related Topics in at-risk Older Adult Populations (R01 Clinical Trial Required) NEW!

Description: The National Institute on Aging (NIA) invites applications for the implementation of investigator-initiated multi-site clinical trials (at all phases or stages) of interventions focused on specific aging-related issues and aimed at reducing the transmission, risk, morbidity, mortality, severity, or complications of COVID-19.

Topics:

• Efficacy and safety of interventions that target aging-related biological mechanisms that may influence risk or severity of COVID-19 infection among at-risk older adults
• Efficacy and safety of preventive and treatment interventions in older patients with differing comorbid conditions that make them especially vulnerable to adverse outcomes of COVID-19 infection
• Effectiveness of health and/or custodial care practices to reduce transmission risk or improve outcomes of COVID-19 infection in nursing homes or other residential settings serving at-risk older persons, including the development and testing of infection control training procedures for healthcare workers
• Rapid pragmatic trials in (at least two) health systems, nursing homes, or adult living facilities, ensuring replication across large pragmatic trial sites and leveraging electronic health records to promote quality improvement in physician, hospital, palliative care, and hospice practices to improve outcomes for older patients with COVID-19, especially those with cognitive impairment, Alzheimer’s disease or Alzheimer’s disease-related dementias (AD/ADRD), or underlying comorbidities
• Trials in at-risk older adults aged 65 and older for whom electronic medical records are available and long-term outcomes can be tracked and in institutions serving those populations
• Trials in older adults with AD/ADRD, older adults from populations with NIH-defined health disparities, and/or other vulnerable populations (e.g., incarcerated, homeless, living in institutions)

Due Dates: 8/3/2020, 9/1/2020, 10/1/2020, 11/2/2020, 12/1/2020, 1/4/2021, and 2/1/2021
Budget: Not Limited

Community Interventions to Address the Consequences of the COVID-19 Pandemic among Health Disparity and Vulnerable Populations (R01- Clinical Trial Optional)

Description: The National Institutes of Health has announced an R01 funding opportunity encouraging applications to implement and evaluate community interventions testing 1) the impacts of mitigation strategies to prevent COVID-19 transmission in NIH-designated health disparity populations and other vulnerable groups; and 2) already implemented, new, or adapted interventions to address the adverse psychosocial, behavioral, and socioeconomic consequences of the pandemic on the health of these groups.

Topics:

• Research topics of interest relate to the behavioral, social, socioeconomic and health impacts of the COVID-19 pandemic with respect to health disparity and vulnerable populations. See the solicitation for a list of example topics.

Due Dates: 8/28/2020 and 12/1/2020
Budget: $500,000 in direct costs

Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19 (R01 – Clinical Trial Optional) NEW!

Description: The NIH has announced a funding opportunity focusing on the role and impact of digital health interventions, (e.g., mobile health [mhealth], telemedicine and telehealth, health information technology [IT], and wearable devices) to address access, reach, delivery, effectiveness, scalability and sustainability of health assessments and interventions for secondary effects (e.g., behavioral health or self-management of chronic conditions) that are utilized during and following the COVID-19 pandemic, particularly in populations that experience health disparities and vulnerable populations.

Topics: See the solicitation for a detailed description of relevant topics and high-priority study areas

Due Dates: 8/20/2020, 12/2/2020, and 3/2/2021
Budget: $750,000 in direct cost per year for up to 3 years

NOSI: Competitive and Administrative Supplements for Community Interventions to Reduce the Impact of COVID-19 on Health Disparity and Other Vulnerable Populations

Description: The NIH has released a Notice of Special Interest for competitive and administrative supplements to test community interventions focused on preventing (or slowing) COVID-19 transmission, evaluate local and state policies and programs intended to mitigate COVID-19 exposure and improve adherence, and reduce the negative impact of the multifaceted consequences on the health of populations that experience health disparities and other vulnerable groups.

Topics:

• Mitigation strategies in populations who experience health disparities and other vulnerable groups
• Evaluating community interventions (existing, new, or adapted) to ameliorate the negative health impacts of the COVID-19 pandemic in populations with health disparities and other vulnerable populations

Due Dates: Applications are accepted on a rolling basis until 12/15/2020.
Budget: $250,000 in direct costs

NOSI: Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19

Description: The NIH has released a Notice of Special Interest highlighting its interest in research to strengthen the healthcare response to COVID-19 and to future public health emergencies, including pandemics. While research on the direct clinical effects of COVID-19 is supported by other funding opportunities, the purpose of this NOSI is to support research to address the secondary health effects of social, behavioral, and economic changes, particularly among populations who experience health disparities and vulnerable populations through the use of digital health assessments and interventions to yield measurable near-term impact. Support will be provided through administrative supplements and competitive revisions to existing grants.

Topics:

• Strategies to increase the reach, access, engagement, efficiency, quality and sustainability of existing evidence-based or validated digital health interventions to address healthcare needs of health disparate and other vulnerable populations, including screening, prevention, self-management, wellness behaviors and treatment both during and following the pandemic
• Studies to evaluate the near-term impact of replacement (or substitution) of face to face services with digital health as a result of the pandemic to address health disparities and vulnerable population needs

Due Dates: Applications are accepted on a rolling basis until 12/15/2020.
Budget: $200,000 in direct costs

NOSI: Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)

• PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements for NIH grantees applying to expand the scope of their active grant.
• PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative Agreements to provide funds for NIH grantees where the work proposed in the supplement is fully within the scope of the ongoing grant.

Topics:  NIA – Mission critical areas as they relate to the COVID-19 pandemic. NIMH – Applications addressing care for new or worsening mental health needs and/or suicide risk in midlife and older age adults will be seen as a high priority.

Due Date: Rolling until 5/1/2021
Budget: Limited to no more than that amount of the current parent award.

NOSI: Availability of Emergency Competitive Revisions on Coronavirus Disease 2019 (COVID-19) for Currently Active NHLBI Phase I-III Clinical Trials

Description: NHLBI is issuing this Notice of Special Interest due to the urgent need for early phase clinical trials to evaluate new or existing interventions that may prevent or treat COVID-19. NHLBI seeks to leverage existing clinical trials expertise and, using NHLBI programs that are actively conducting Phase I-III clinical trials, to rapidly initiate and conduct Phase I-Phase I/II (bridging) clinical trials in patients at risk for SARS-CoV-2 infection and/or patients with COVID-19.

Topics: Safety and efficacy of interventions for primary prevention and/or treatment of COVID-19, associated clinical phenotypes, and surrogate outcomes, relevant to heart, lung, and blood (HLB) diseases

Due Dates: 10/5/2020
Budget: Not specified

NOSI: Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)

Topic: COVID-19 related research including host response, associations with heart, lung, and blood (HLB) diseases, potential impacts on transfusion safety, and clinical outcomes of infected individuals.

Due Date: Rolling, through 10/5/2020
Budget: Not specified

Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)

R21 (Clinical Trial Not Allowed)
R01 (Clinical Trial Not Allowed)

Description: NIAID has announced an expedited funding mechanism for research on SARS-CoV-2 and/or COVID-19.

Topics:

• Studies to understand critical aspects of viral transmission, infection, replication and pathogenesis
• Identification and characterization of the onset and duration of immunity in healthy and at-risk populations
• Virologic and serologic surveillance studies and natural history studies to understand the origin of the virus including the animal host reservoir, potential intermediate hosts, factors leading to spill over events, evidence of continued spill over events and studies at the human-animal interface
• Studies to assess and characterize the natural history and long-term consequences of SARS-CoV-2 infection in various human populations including at risk populations
• Development or improvement of clinical diagnostic tests for SARS-CoV-2 to increase the sensitivity, specificity and ability to provide rapid results
• Development and testing of SARS-CoV-2 therapeutic candidates in relevant in vitro, ex vivo or animal models
• Development of SARS-CoV-2-specific or broadly protective coronavirus vaccine candidates
• Studies to inform the development of vaccination strategies for at-risk populations including use of age-specific adjuvants or novel antigen formulations/dosing
• Development of assays and animal models to evaluate the potential of enhanced disease after vaccination for SARS-CoV-2
• Assess animal models for SARS-CoV-2 and how the models compare to human infection including animal models that represent at risk populations (elderly, immunocompromised, very young, pregnant models)
• Development of animal models for transmission experiments;
• Development of organoid culture models and/or ex vivo explant models
• Computational modeling studies to identify and evaluate interventions to protect at-risk populations and for making public health policy decisions for control and mitigation measures
• Study interactions and impact between SARS-CoV-2 and other respiratory pathogens including influenza (e.g., co-infections, interference)
• Comparative studies of SARS-CoV-2 to other coronaviruses including SARS-CoV-1 and MERS
• Data science approaches to develop algorithms, models, and informatics solutions

Due Dates: Accepting applications on a rolling basis until 4/30/2021
Budget: $275,000 in direct costs for R21; No specified limit for R01

NOSI: Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)

Topics: Viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against SARS-CoV-2/COVID-19.

Due Date: Rolling until 3/25/2021
Budget: Not Specified

NOSI: Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2

Topics: Predictive models for the spread of SARS-CoV-2 and other related infectious agents (all relevant grants). Repurposing or modification of diagnostic tools currently under development to enable rapid detection of SARS-CoV-2 infection; rapid development of potential therapeutic agents for COVID-19 (SBIR/STTR grants only).

Due Date: Rolling, through 2/6/2021
Budget: Not Specified

Notice of Special Interest (NOSI): New Administrative Supplement Applications to UL1 and U24 CTSA Awards to Address COVID-19 Public Health Need

The National Center for Advancing Translational Sciences (NCATS) has issued a Notice of Special Interest to solicit applications for Administrative Supplements from current Clinical and Translational Science Award (CTSA) UL1 and U24 award recipients to address COVID-19.

Topics: See the funding opportunity announcement for details of the topics that are specific to UL1 and U24 awards.

Due Dates: Applications are accepted on a rolling basis through 11/10/2020.
Budget: Not specified

NOSI: Availability of Emergency Competitive Revisions and Administrative Supplements to Clinical and Translational Science Award (CTSA) Program Awards to Address 2019 Novel Coronavirus Disease (COVID-19) Public Health Needs

The NCATS is seeking proposals for emergency administrative supplements and competitive revisions to existing UL1 and U24 CTSA Program awards to address COVID-19 public health needs

Topics:

• Digital health platforms
• Planning of COVID-19 trials
• eConsent support
• Platforms for meta-analysis of COVID-19 trials
• Clinical data provision
• Clinical studies and trials of COVID-19 interventions
• Assessment of infectious or convalescent status

Due Dates: Applications will be reviewed on a rolling basis through 11/10/2020
Budget: Not specified, but may exceed the current amount of the parent award

NOSI: Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Heath Need

Topics: Use of informatics solutions to diagnose cases and the use of CTSA-supported core resources to facilitate research on COVID-19 and advance the translation of research findings into diagnostics, therapeutics, and vaccines.

PA-18-591 – Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

Due Dates: 11/2/2020
Budget: Application budgets are limited to no more than the amount of the current parent award and must reflect the actual needs of the proposed project.

PAR-19-099 – Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative Innovation Award (U01 Clinical Trial Optional) DEADLINE APPROACHING

Due Dates: 7/10/2020, 11/9/2020, 3/8/2021, 7/9/2021
Budget: $400,000 – $750,000

PAR-19-100 – Limited Competition: Clinical and Translational Science Award (CTSA) Program: Exploratory Collaborative Innovation Awards (R21 Clinical Trial Optional)

Due Dates: 7/10/2020, 11/9/2020, 3/8/2021, 7/9/2021
Budget: $275,000 (direct costs)

PAR-19-337 – Limited Competition: Competitive Revision Awards for the Clinical and Translational Science Award (CTSA) Program (U54 Clinical Trial Optional).

Due date: 9/25/2020
Budget: $750,000/year in direct costs excluding consortium/contractual F&A costs.

NOSI: Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19)

Topics: Using innovative processes to identify the therapeutic/indication pair for use to treat COVID-19.

PA-18-462 – Clinical Trial Planning: Therapeutic/Indication Pairing Strategies (U34) (Clinical Trial Not Allowed)

Due Dates: 10/16/2020
Budget: $225,000 (direct costs)

PAR-18-332 – Clinic Testing Therapeutic/Indications Pairing Strategies (U01 Clinical Trial Required)

Due Dates: 10/5/2020
Budget: $3,000,000 in direct costs per year.

NOSI: Administrative Supplements for Tissue Chips Research on the 2019 Novel Coronavirus

Topic: Use of microphysiological systems or tissue chips in collecting and examining data on the risks and outcomes for COVID-19 infection, and advance the translation of research findings into diagnostics, therapeutics, and vaccines.

Due Date: Rolling through 01/26/2022
Budget: 25% total costs of current parent award

NOSI: Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus

Topic: NIDA is interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders.

Due Date: Rolling, through 3/31/2021
Budget: Maximum of $100,000 direct costs per year for 2 years.  Higher budgets may be considered with justification.

NOSI: NIDCD is Interested in Supporting Research on the Impact of COVID-19 on Mission Specific Sensory and Communication Disorders

Description: NIDCD invites applications for research on COVID-19 in relation to NIDCD’s scientific programs of hearing, balance, taste, smell, voice, speech, and language.

Topics: Topics include, but are not limited to, the following:

• The effects of prolonged oral intubation on laryngeal function and voice production
• Short-term and long-term effects of COVID-19 on the auditory, vestibular, or olfactory systems
• The prevalence, onset, and resolution of acquired deficits (i.e., HBTSVSL) among patients with COVID-19 across the lifespan and in association with various underlying genetic predispositions and health conditions
• The molecular mechanisms underlying chemosensory dysfunction due to SARS-CoV-2 infection
• The impact of stress/isolation on speech, language or fluency recovery/development in children or adults
• The impact of potential congenital transmission of maternal SARS-CoV-2 infection to the newborn in relation to the auditory, vestibular, olfactory, or vocal function and/or the impact on speech production or language acquisition
• Potential ototoxicity from therapeutics or vaccination related to COVID-19
• Worsening of communicative function because of physical distancing, sheltering in place, and wearing of protective personal equipment during mitigation of this infectious pandemic
• Telehealth service delivery to individuals with communication disorders
• Multidisciplinary collaborative teams including clinicians, basic biologists, geneticists, quantitative scientist, epidemiologists, or other researchers to study COVID-19 related human conditions and behaviors, bioethical considerations, health-service delivery, health services in low-resource areas, and health disparities within NIDCD mission areas

Due Dates: Various program-specific due dates on or after 10/5/2020
Budget: Varies by program

NIBIB has issued a shared set of topics and three separate NOSIs for current grantees, SBIR/STTR applicants, and all other applicants:

Current Grantees NOSI
SBIR/STTR Applicants NOSI
All Other Applicants NOSI

Topics: Rapid diagnostics, wearable/implantable sensors, digital health platforms, healthcare training platforms, robotic technologies to limit caregiver exposure, ventilators, and disinfectant technologies

Due Date: Varies by NOSI
Budget: Varies by NOSI

Rapid Acceleration of Diagnostics (RADx)

Description: NIBIB is providing substantial support to accelerate the development, validation, and commercialization of innovative point-of-care and home-based tests, as well as improvements to  clinical laboratory tests, that can directly detect SARS-CoV-2, the virus that causes COVID-19. NIBIB will support the full range of product development including, commercialization and product distribution. RADx will support novel solutions that build the U.S. capacity for SARS-CoV-2 testing up to 100-fold above what is achievable with standard approaches.

Topics: SARS-CoV-2 diagnostic testing technologies in two stages:

• Early stage: transformative innovations based on novel testing strategies that have potential for major scale up
• Advanced stage: modification and optimization of existing SARS-CoV-2 testing approaches, including clinical laboratory tests, that can dramatically increase testing capacity

Due Dates: Rolling
Budget: Not specified

NOSI: Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Biological Effects of the 2019 Novel Coronavirus on the Nervous System

Description: NINDS is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19) and on biological effects on the nervous system of its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Research of interest must fall within NINDS’s scientific mission, which is to support basic, translational, and clinical neuroscience research to expand fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.

Topics: Biology, pathophysiology, prevention, diagnosis, sequelae, or treatment of the 2019 Novel Coronovirus

Due Dates: Applications accepted on a rolling basis until 4/14/2021
Budget: $200,000 in direct costs

NOSI: Availability of Urgent Competitive Revisions and Administrative Supplements for Coronavirus Disease 2019 (COVID-19) Research within the Mission of NIDCR

Description: The National Institute of Dental and Craniofacial Research (NIDCR) has issued a Notice of Special Interest to highlight the urgent need for research on COVID-19 and will place a high priority on topics that would be of immediate and high impact to protect and ensure the safety of personnel and patients in dental practices.

Topics:

• Prevention of SARS-COV-2 transmission
• Improvements in the detection and diagnosis of COVID-19
• Acquisition of a more robust understanding of SARS-CoV-2 pathogenesis
• Influence and interaction of sex (a biological variable) and gender (a social construct), race and ethnicity in relation to COVID-19
• COVID-19 risk, prevention, and health outcomes

Due Dates: 11/2/2020
Budget: $150,000 in total direct costs

NOSI: Availability of Administrative Supplements & Urgent Competitive Revisions to NCCIH Grants for Natural Product Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) & Coronavirus Disease 2019 (COVID-19)

Description: The National Center for Complementary and Integrative Health (NCCIH) has announced the availability of funds for Administrative Supplements or Urgent Competitive Revisions to promote research on the effects of natural products alone or in combination with other complementary and integrative health approaches on SARS-CoV-2 and COVID-19.

Topics: Research on the therapeutic and/or mechanistic effects on SARS-CoV-2/COVID-19 of natural product–based complementary remedies including, but not limited to: herbal therapies, vitamins, supplements, probiotics, microbial therapies, and Chinese medicine herbal preparations.

Due Dates: Applications are accepted on a rolling basis through 8/17/2020.
Budget: $150,000 in direct costs

Emergency Awards: Research Projects in SARS-CoV-2 Serological Sciences (U01 Clinical Trial Optional)

Description: The NCI has announced the availability of grant funding through the cooperative agreement mechanism U01 for SARS-CoV-2 research projects that will be part of a Serological Sciences Network (SeroNet).

Topics:

• Identifying and advancing research opportunities to characterize the immune responses elicited by SARS-CoV-2 viral infection
• Understanding the mechanisms driving the serological, humoral, and cellular immune responses
• Determining host, genetic, and environmental modifiers of the immune response
• Determining the serological correlates of disease pathogenesis and protection against future infection
• Defining access, communication, and implementation barriers related to SARS-CoV-2 serological testing

Due Dates: 7/22/2020
Budget: $500,000 in direct costs

Emergency Awards: SARS-CoV-2 Serological Sciences Centers of Excellence (U54 Clinical Trial Optional)

Description: The NCI has announced a cooperative agreement (U54) funding opportunity to establish Serological Sciences Centers of Excellence to identify and advance research opportunities related to SARS-CoV-2 viral infection and serological testing .

Topics:

• Characterizing the immune responses elicited by SARS-CoV-2 viral infection
• Understanding the mechanisms driving the serological, humoral and cellular immune responses
• Determining host, genetic, and environmental modifiers of the immune response
• Determining serological correlates of disease pathogenesis and protection against future infection
• Defining access, communication, and implementation barriers related to SARS-CoV-2 serological testing

Due Dates: 7/22/2020
Budget: $1.5M in direct costs

NOSI: Limited Competition for Emergency Competitive Revisions for Community-Engaged Research on COVID-19 Testing among Underserved and/or Vulnerable Populations

View solicitation for projects involving community collaborations or partnerships.

View solicitation for projects involving large-scale networks, consortia, centers, and other current programs that have adequate capacity, infrastructure, and established community-engaged relationships to support large-scale testing.

Description: The NIH has announced funding for competitive revisions to existing awards to support two-year community-engaged Testing Research Projects examining SARS-CoV-2 infection patterns and efforts to increase access and effectiveness of diagnostic methods through the Rapid Acceleration of Diagnostics for Underserved Populations (RADx-UP) initiative. The overarching goal is to understand factors that have led to disproportionate burden of the pandemic on these underserved populations so that interventions can be implemented to decrease these disparities.

Topics:

• Increasing reach, access, uptake, and impact for COVID-19 testing in underserved and/or vulnerable populations
• Creation of strategies to widely disseminate up-to-date FDA-authorized/approved testing technology based on detection of viral nucleic acids and consider viral detection point-of-care tests, including antigen and antibody tests that emerge from NIH-supported technology development programs, to underserved and/or vulnerable populations

Due Dates: 8/7/2020
Budget: $700,000 in direct costs (NOT-OD-20-120); $3.5M in direct costs (NOT-OD-20-121)

NOSI: Emergency Competitive Revisions for Social, Ethical, and Behavioral Implications (SEBI) Research on COVID-19 Testing among Underserved and/or Vulnerable Populations

Description: As part of the RADx-UP initiative, the NIH has announced a SEBI NOSI for projects to identify, analyze, and address the social, ethical, and behavioral factors likely to influence access and uptake of COVID-19 testing in underserved and/or vulnerable populations.

Topics: Topics of interest include but are not limited to:

• Which social, ethical and behavioral facilitators and barriers substantially influence decisions about whether and when to offer or seek COVID-19 testing?
• What strategies mitigate barriers, and increase access to and acceptability of testing and repeat testing?
• What are implications of both positive and negative COVID-19 diagnostic tests for underserved and/or vulnerable groups, and how do they influence testing decisions and downstream beliefs and behaviors?
• How are test results interpreted and used in these underserved and/or vulnerable communities?
• What are the risks and benefits of implementing new COVID-19 testing technologies in underserved and/or vulnerable communities from the perspectives of those populations?
• What population specific social, ethical, or behavioral factors should be addressed before deploying novel testing strategies?
• What factors should be addressed before vaccine trials can be considered?
• What strategies can be developed and tested to increase acceptability of vaccine trials and vaccinations in underserved and/or vulnerable populations?

Due Dates: 8/7/2020, 9/8/2020
Budget: $400,000 in direct costs

Emergency Awards: RADx-UP Coordination and Data Collection Center (CDCC) (U24 Clinical Trial Optional)

Description: This emergency cooperative agreement funding opportunity announcement (FOA) from the National Institutes of Health (NIH) provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Underserved Populations (RADx-UP) initiative, a consortium of community-engaged research projects to understand factors that have led to disproportionate burden of the pandemic on the underserved and/or vulnerable populations so that interventions can be implemented to decrease these disparities. This FOA seeks to fund a single Coordination and Data Collection Center (CDCC) as an integral part of the consortium.

Topics: See the funding opportunity announcement for details of the objectives of the CDCC

Due Dates: 8/7/2020
Budget: $5M in annual direct costs

View Letter

The NSF encourages investigators to use existing NSF funding mechanisms to submit proposals to conduct non-medical, non-clinical-care research that can be used immediately to explore how to model and understand the spread of COVID-19, to inform and educate about the science of virus transmission and prevention, and to encourage the development of processes and actions to address this global challenge.

For proposals of up to $200K, NSF encourages using the Rapid Response Research (RAPID) funding mechanism, which allows NSF to receive and review proposals having a severe urgency.

View Letter

The Office of Advanced Cyberinfrastructure (OAC) within the Directorate for Computer and Information Science and Engineering is inviting RAPID proposals and supplemental funding requests to existing awards that address COVID-19 challenges through data and/or software infrastructure development activities.

In response to the current need for more COVID-19 information, certain NIFA programs will allow submission of COVID-19 relevant projects outside of their normal deadlines.

Agriculture and Food Research Initiative (AFRI)

View Solicitation

Topics: Focus areas of interest include, but are not limited to the following:

• Animal Nutrition, Growth and Lactation (A1231)
• Critical Agricultural Research and Extension (CARE) (A1701)
• Diseases of Agricultural Animals (A1221)
• Food Safety and Defense (A1332)
• Foundational Knowledge of Plant Products (A1103)
• Economics, Markets, and Trade (A1641)

Due Date: Varies by Program
Budget: $1,000,000

The Bill & Melinda Gates Foundation, Wellcome, and Mastercard have committed up to $125 million in seed funding to speed-up the response to the COVID-19 epidemic by identifying, assessing, developing, and scaling-up treatments. The COVID-19 Therapeutics Accelerator will play a catalytic role by accelerating and evaluating new and repurposed drugs and biologics to treat patients with COVID-19 in the immediate term, and other viral pathogens in the longer-term.

View Announcement

Topics: The Accelerator is seeking partners for the following activities:

• Identifying candidate compounds by testing approved drugs for activity against COVID-19, screening libraries of compounds with confirmed safety data, and considering new investigational compounds and monoclonal antibodies.
• Developing drugs or monoclonal antibodies that pass initial screening.
• Scaling up production and commercialization of successful drugs and monoclonal antibodies.

Due Date: Not Specified
Budget: Not Specified; Total Program Budget – $125,000,000

NIST Manufacturing USA National Emergency Assistance Program

NIST invites applications from the 2,000 current Manufacturing USA institutes, including small manufacturers, two-thirds of Fortune 50 U.S. manufacturers, and nearly every top ranked research and engineering university in the United States.

View Solicitation

Topic: Projects should focus on responding to the COVID-19 pandemic. Projects may include medical countermeasures; non-medical countermeasures; leveraging institute capabilities to strengthen state and community resilience; grants to companies and technical support to accelerate productions of critical materials, equipment, and supplies; creation of additional production facilities; technology roadmapping for pandemic response and recovery; reshoring the manufacture of critical conventional drugs and ensuring supply chain for critical materials related to pandemic response; or workforce development and training for a skilled advanced manufacturing workforce.

Due Date: Rolling
Budget: $250,000 – $10 million

No opportunities available right now

No opportunities available right now

Special Call for COVID-19 Projects - Partnership Opportunities in Support of Discovery, Translational and Clinical Trial Stage Activities

View Solicitation

Description: Focusing on the development of therapies for COVID-19, CIRM has issued a special announcement to support promising discovery, preclinical and clinical trial stage projects that could quickly advance new treatments.

Topics:

• Cell-based COVID-19 therapies that use, target, or are manufactured using stem or progenitor cells
• Gene therapies for COVID-19 that are intended to replace, regenerate, or repair the function of aged, diseased, damaged, or defective cells, tissues, and/or organs

Due Date: Biweekly on an ongoing basis
Budget: $150,000 - $750,000 depending upon product stage

Fast Grants are available exclusively to PIs at academic institutions already working on COVID-19 related projects that could help with the pandemic within the next six months.

View Solicitation

Topics: All COVID-19 related science

Due Date: Rolling, award decisions made in 48 hours.
Budget: $10,000 - $500,000

PCORI is requesting enhancements to existing Research Projects and Engagement Awards.

COVID-19-Related Enhancements to Existing PCORI-Funded Research Projects

COVID-19-Related Enhancements to Existing PCORI-Funded Engagement Awards

Topics: Modest additions to existing aims as they relate to COVID-19 or new aims designed to produce useful knowledge related to COVID-19 and the original award.  Taking advantage of natural experiments in health system, state, and provider responses is strongly encouraged.

Due Date: Rolling submissions
Budget: $500,000 for Research Projects; $150,000 for Engagement Awards

2020 Call for Code Global Challenge

Description: The 2020 Call for Code Global Challenge is a competition in which Call for Code is asking innovators to create practical, effective, and high-quality applications based on one or more IBM Cloud™ services (for  example, web, mobile, data, analytics, AI, IoT, or weather) to mitigate the  impact of COVID-19. 

Topics: Creation of IBM Cloud™-based, open-source applications to mitigate the impact of COVID-19, for example, by improving crisis communications or fostering remote learning and community cooperation.

Due Dates: 7/31/2020
Budget: One $200,000 grand prize; two $25,000 first and second runner-up prizes; two $10,000 third and fourth runner-up prizes

West Coast Consortium for Technology & Innovation in Pediatrics (CTIP)

Description: The West Coast Consortium for Technology & Innovation in Pediatrics (CTIP) is announcing a limited grant opportunity to support pediatric medical device innovators who are able to use their technology to aid in the current COVID-19 pandemic.

Topics: Pediatric medical device development or adaptation to manage the impact of COVID-19 on children

Due Dates: Accepting applications on a rolling basis
Budget: $15,000

Emergency Response for the Health Care System – Innovation Challenge

Description: This challenge encourages applicants to design a novel digital tool to support the health care system during a large-scale health crisis.

Topics: Digital health tools addressing various topics, including:

• Capacity management
• Clinical integration (to coordinate patient care)
• Communication
• Data analytics, tracking, and visualization
• Data exchange
• Mental health tools for providers

Due Dates: 8/18/2020 (Phase II)
Budget: Five semifinalists will receive $1,000 prizes; three finalists will receive prizes of $5,000 (3^rd place), $15,000 (2^nd place), and $25,000 (1^st place)

Emergency Response for the General Public – Innovation Challenge

Description: This challenge encourages applicants to design a digital health technology tool to support the needs of individuals affected by a large-scale health crisis.

Topics: Digital health tools addressing the needs of individuals, including:

• Health care access
• Medication access
• Access to other essential resources (e.g., diagnostic testing)
• Information dissemination (e.g., clinical guidelines and recommendations)
• Communication
• Behavioral and emotional health

Due Dates: 8/18/2020 (Phase II)
Budget: Five semifinalists will receive $1,000 prizes; three finalists will receive prizes of $5,000 (3^rd place), $15,000 (2^nd place), and $25,000 (1^st place)

Broad Agency Announcement for COVID-19 Seedling Research Topics (IARPA-BAA-20-01) DEADLINE APPROACHING

Description: The Intelligence Advanced Research Projects Activity (IARPA) has released a Broad Agency Announcement for quick-turnaround projects for COVID-19 research topics.

Topics:

• Detection and sensing

• Supply chain management and integrity

• Geo-spatio-temporal monitoring and mapping, with privacy protection

• Information reliability and collaboration tools

• Modeling, simulation, and predictive analytics

Due Dates: 7/7/2020
Budget: Less than $1,000,000

Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro - FAPERJ

Emergency Action Projects to Combat the Effects of Covid-19 - FAPERJ / SES Partnership - 2020

Description: FAPERJ is providing funding to continue the work of networks in Brazil studying emerging and reemerging viruses and to finance the study of Covid-19 and the SARS-CoV-2 virus by various organizations, including startups and small, micro, and medium-sized companies based in the State of Rio de Janeiro.

Topics:

• Genomics
• Pathophysiology of the disease
• Clinical aspects
• Diagnosis of the disease
• Epidemiology
• Virus-host interaction
• Development of diagnostic kits
• Disease control and coping strategies
• Innovative solutions to expand supplies of items such as masks, alcohol gel, and respirators

Due Dates: Applications are accepted on a rolling basis
Budget: Not specified

Finep

Genome Canada

COVID-19 Regional Genomics Initiative

Description: Genome Canada is issuing a funding opportunity to support regional genomics projects designed to address specific, short-term needs of industry, not-for-profit, and public sector recipients through research conducted by academics in collaboration with these recipients. Projects are expected to be outcome-driven, small-scale or larger (depending on other funding sources) and focused on delivering a genomics-based solution to help address the current crisis in the near term.

Topics: Examples of relevant topics include:

• Identifying and detecting COVID-19 infections
• Understanding mechanisms of infection
• Mapping the spread in real time
• Tracking new mutations
• Developing drug treatments or vaccines for the disease

Due Dates: Accepting applications on a rolling basis until 7/1/2020
Budget: Not specified ($250,000 [CAD] allocated per Genome Center)

National Research Council Canada

National Research Council Industrial Research Assistance Program (NRC IRAP)

Description: NRC Canada is offering project funding to small and medium-sized businesses that are working to provide COVID-19 solutions in the form of goods or services to health care workers and public health officials currently fighting the pandemic.

Topics: Development of COVID-19 solutions for health care workers and public health officials

Due Dates: None; applicants directly contact an Industrial Technology Advisor at NRC
Budget: Not specified

Solutions for the next human high-impact pandemic

Description: Eureka is seeking proposals for collaborative projects involving at least two independent organizations from different participating countries.

Topics: Topics include (but are not limited to):

• Technologies enabling local resilience or self sufficiency
• Medical intervention robotics
• Infection prevention and protection
• Prevention of antibiotic resistance
• Sanitation technology
• Diagnostics and testing
• Therapeutics, vaccines and medicines
• Medical intervention robotics
• Disease-tracking technology
• Smart technologies for critical production and supply chains under lockdown
• Education technologies and digital workplace
• Govtech/Open data and Big Data

Due Dates: 7/15/2020
Budget: Not specified

AMable/European Commission

AMable Open Call for Solution Ideas (COVID-19)

Description: AMable is seeking challenges related to COVID-19 and solutions that use additive manufacturing.

Topics: Challenges will involve a lack of equipment, helpful tools, replacement parts or parts that enable additional functionality.

Due Dates: 10/1/2020
Budget: €10,000 per challenge

The European Commission

No current opportunities

DIM ELICIT

Special call for proposals: Development of innovative technologies & methods to fight SARS-CoV-2

Description: The DIM ELICIT organization would like to support collaborative projects developing innovative technologies and methods for the analysis, diagnosis and/or treatment of SARS-CoV-2. The program is open to research teams in the Ile de France region.

Topics: The technologies targeted in this call must belong to at least one core technology and one end-user application from the following lists:

Core technologies:

• Microfludics
• Biophotonic and waves
• Image analysis and Big Data

End-user applications:

• Single cell/Single molecule
• Organ-on-a-chip
• Technologies for in vivo biology
• High-tech, low-cost technologies

Due Dates: Applications are accepted on a rolling basis
Budget: €15k for running and/or staff costs; €30k for equipment

Agence Nationale de la Recherche (ANR)

Research Action COVID-19 (RA-COVID-19)

Description: The ANR is launching a new call for Research-Action projects on COVID-19, focusing on WHO recommendations.

Topics:

• Epidemiological studies
• Physiopathogenesis of the disease
• Infection prevention and control
• Ethics and social dynamics
• Global issues of the Covid-19 epidemic

Due Dates: 10/28/2020
Budget: €150,000

Merck KGaA

Research Grant for Pandemic Preparedness

Description: Merck will consider proposals that leverage technological solutions to be more prepared for pandemic outbreaks or solutions that could help to fight emerging viral infections.

Topics:

Pre-outbreak R&D Preparedness for pandemic disease:

• Assessing the priority of pathogens and diseases with epidemic threat
• Platform technologies to accelerate the development of vaccines, drugs, diagnostics, vector control tools and delivery systems needed to control emerging health threats
• Innovative technologies for better personal protection equipment for infection control

Response during outbreak:

• Novel health technologies (e.g. AI, bioelectronics, diagnostics) for early screening of potential infected patients and treatment facilitation.
• Fast-track identifying, testing and production of effective drugs and vaccines during outbreak

Due Dates: Applications will be reviewed on a rolling basis
Budget: €500,000 per year

Federal Ministry of Education and Research, Germany NEW!

Special program to accelerate research and development of urgently needed vaccines against SARS-CoV-2

Description: Germany’s Federal Ministry of Education and Research has issued a funding guideline with the aim of ensuring the early and extensive provision of an effective and safe vaccine in Germany by accelerating vaccine development.

Topics:

All proposals must address the following areas:

• Clinical vaccine development in phases I - III. Clinical development must be based on vaccine candidates against SARS-CoV-2 for which preclinical development has progressed to such an extent that the first clinical trials can be started before November 15, 2020 if possible.
• The early expansion of manufacturing and filling capacities (also by placing orders). The recipient's own production and filling capacities must be built up or expanded in Germany. This includes, in particular, preparatory work and procurement processes that are necessary with a view to seamlessly starting the subsequent test phase as well as preparatory work and procurement processes that arise in clinical development before approval and that are necessary to expand and secure production capacities in parallel with approval and afterwards (e.g., costs for filling capacities).
• The expansion of clinical trial capacities in Germany. This includes in particular the inclusion of additional subjects in the clinical trials in phases II to III.

Due Dates: 7/15/2020
Budget: Not Specified

Deutsche Forschungsgemeinschaft (German Research Foundation)

View Solicitation (English)

Topics: Prevention, early detection, containment and investigation of the causes, impacts and management of epidemics and pandemics

Due Date:  Full Proposal – 9/1/2020
Budget: Not Specified

Government of India, Ministry of Science & Technology/Biotechnology Industry Research Assistance Council (BIRAC) NEW! DEADLINE APPROACHING

Anti- SARS-CoV-2 /nCoV-2 Virus Studies Using  Botanical Ingredients and Traditional Formulations DEADLINE APPROACHING

Description: The Ministry of Science and Technology of the Government of India has released a call for proposals for projects exploring medicinal and aromatic plants as sources of new therapeutics for COVID-19.

Topics:

• Development of experimental models for evaluation of anti-viral activity of extracts, fractions, and phytochemical constituents from medicinal and aromatic plants
• Screening of extracts, fractions, phytochemical constituents, and traditional formulations from medicinal and aromatic plant against SARS-CoV2
• Studies on extracts, fractions, and phytochemical constituents from medicinal & aromatic plants

Due Dates: 7/3/2020
Budget: Rs. 100 lakhs (approximately $132,000 [USD])

Malta Council for Science and Technology and Malta Enterprise Corporation

COVID-19 R&D Fund

Description: The Malta Council for Science and Technology and Malta Enterprise Corporation have announced a €5.3 Million COVID-19 R&D Fund targeting public, academic, and private entities to enable R&D on COVID-19. The fund is especially interested in projects with outcomes not only addressing innovative and/or improved approaches related to the current pandemic but also potential future waves and other antiviral relevant research.

Topics:

• Relevant medicinal products (including vaccines) and treatments, their intermediates, active pharmaceutical ingredients and raw materials
• Medical devices, hospital and medical equipment (including ventilators and protective clothing and equipment as well as diagnostic tools) and necessary raw materials
• Disinfectants and their intermediary products and raw chemical materials necessary for their production
• Data collection and processing tools related to innovative and/or improved approaches with regards to current and/or future infectious disease prevention; o trajectory of the epidemic/pandemic disease
• Better dissemination of recommendations by national (Public Health) and/or international health authorities (WHO)
• Any other research related to infectious diseases that can lead to epidemics in humans

Due Dates: Applications are accepted on a rolling basis until 11/30/2020.
Budget: Not specified

Ministry of Science and Innovation

Solicitud Urgente de Expresiones de Interés para la Financiación Extraordinaria de Proyectos de Investigación sobre el SARS-CoV-2 y la Enfermedad COVID-19 (Spanish)

Topics:

• Scalable rapid diagnostic techniques for SARS-CoV-2, especially related to early stage detection and healthcare stratification
• Clinical, biological, and molecular characteristics of COVID-19
• Therapeutic development, including pharmaceutical and non-pharmaceutical measures
• Antiviral resistance studies
• Vaccine development
• Socioeconomic impact of COVID-19
• Integrated epidemiological controls, including AI and Big Data

Due Date: Ongoing
Budget: Not Specified; Total Program Budget €24,000,000

Vinnova

Innovations to mitigate the crisis: Finding new ways in the time of a crisis

Description: Vinnova is calling for innovative ideas to address the wider impact of the coronavirus crisis and support Swedish society. New solutions should be ready to be put into practice within six to twelve months.

Topics: Any new coronavirus-related need addressed through the conversion of production or activities, where a first solution is ready within 6-12 months

Due Dates: 8/21/2020
Budget: Up to SEK 1,000,000

Vinnova NEW!

Innovation projects in the health field that dampen the prevalence and effects of the COVID-19 pandemic

Description: Vinnova (Sweden) has issued a call for proposals for collaborative health-related innovation projects and feasibility studies to help curb the spread and effects of the COVID-19 pandemic and prevent future pandemics.

Topics: See the solicitation for a description of relevant topics.

Due Dates: 8/18/2020
Budget: 5,00,000 SEK

Vinnova NEW!

Pre-studies for innovation projects in the health area that prevent future pandemics

Description: Vinnova’s pre-studies opportunity is aimed at supporting feasibility studies, i.e., shorter projects where conditions and plans for implementing a more extensive research and innovation project are developed and which focus on future pandemics.

Topics: See the solicitation for a description of relevant topics.

Due Dates: 8/18/2020
Budget: 1,000,000. SEK

UK Research and Innovation (UKRI)

Proposals will be accepted from anyone who is normally eligible to apply for UKRI funding. You will need to show that you can start work within 4 weeks of the funding being confirmed.

View Solicitation

Topics: Short-term projects (12-18 months) addressing and mitigating the health, social, economic, cultural and environmental impacts of the COVID-19 outbreak.

Due Date: Ongoing
Budget: 80% of the full economic cost

COVID-19 Rapid Response Rolling Call

Description: UKRI has announced a call for proposals for UK-led academic, small and medium-sized enterprise, and wider industry research that will address a wide range of COVID-19 knowledge gaps/needs, and which will lead to a benefit in UK, potentially international, public health within 12 months.

Topics:

• Virology, immunity and pathophysiology
• Diagnostics
• Epidemiology
• Personal protective equipment
• Infection prevention and control measures
• Public Health, Media and Communication
• Clinical Management
• Primary, Adjunctive and Supportive Therapies
• Vaccines
• Health and care delivery
• Assays and animal models
• Research infrastructure

Due Dates: Applications are accepted and reviewed on a rolling basis until 4/1/2021
Budget: Not limited, but must reflect the needs of the research project

Get funding for ideas that address COVID-19

Description: Proposals are invited for short-term projects addressing and mitigating the health, social, economic, cultural, and environmental impacts of the COVID-19 outbreak. 

Topics: An extensive list of research questions can be found at https://www.ukri.org/files/research-questions-for-covid-19/. These questions focus on various areas, including:

• COVID-19 treatments
• Contact tracing
• Epidemiology
• Data availability and use
• Modeling and prediction
• Accelerated use of AI and automation
• National security and geopolitics
• Engineering
• Inequalities
• Behavioral insights

Due Dates: None. Applications are accepted on a rolling basis.
Budget: Not specified